Azacitidine (5 Azacytidine)

A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.

Also Known As:

Networked: 935 relevant articles (84 outcomes, 150 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Fenaux, Pierre: 30 articles (10/2015 - 12/2005)
2.	Garcia-Manero, Guillermo: 23 articles (12/2015 - 07/2007)
3.	Gore, Steven D: 23 articles (03/2015 - 03/2009)
4.	Santini, Valeria: 23 articles (03/2015 - 03/2009)
5.	List, Alan F: 14 articles (09/2015 - 02/2010)
6.	Kantarjian, Hagop: 13 articles (08/2015 - 05/2005)
7.	Hellström-Lindberg, Eva: 12 articles (10/2015 - 01/2006)
8.	Beach, C L: 12 articles (07/2015 - 05/2005)
9.	Seymour, John F: 12 articles (07/2015 - 03/2009)
10.	Silverman, Lewis R: 12 articles (07/2013 - 05/2002)

Related Diseases

1.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/01/2010 - "The earliest and the most successful epigenetic drug to date, 5-Azacytidine, is currently recommended as the first-line treatment of high-risk myelodysplastic syndromes (MDS). " 07/01/2013 - "These results demonstrate azacitidine benefit on overall survival compared with conventional care regimens in patients with higher-risk myelodysplastic syndromes who achieve hematologic response but never attain complete or partial remission, in addition to the survival advantage conferred by achievement of complete or partial remission." 01/01/2013 - "Around 6 weeks after this single azacitidine cycle, complete remission-according to international working group criteria-was observed with continuous improvement in peripheral blood counts to normal values, transfusion-independence, normal blast count (< 5 %) with normal morphology and flow cytometry, as well as a normal bone marrow karyotype and no dysplastic stigmata suggestive of a coexisting myelodysplastic syndrome. " 11/01/2010 - "Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. " 10/15/2006 - "Azacitidine administered in the outpatient setting is well tolerated and can induce complete hematological remission in patients with myelodysplastic syndromes (MDS). "
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2015 - "When compared with best supportive care, azacitidine significantly improved overall survival (hazard ratio [HR], 0.69; 95% CI, 0.54-0.87) and time to acute myeloid leukemia transformation (HR, 0.51; 95% CI, 0.35-0.74). " 11/01/2015 - "First, an acute myeloid leukemia patient showed life-threatening toxicities, but outstanding complete remission, after a single round of azacitidine. " 01/01/2013 - "Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia." 06/01/1982 - "Even when abnormal chromosomes are present, 5-azacytidine can induce complete remission in patients with previously treated ANLL." 01/01/2014 - "We present the first Jehovah's Witness patient with acute myeloid leukemia (AML) treated successfully with azacitidine. "
3.	Leukemia 02/12/2015 - "Recently, azacytidine, a hypomethylating agent, was reported to induce hematologic/molecular remissions in some children with JMML, and its role in both reducing leukemia burden before HSCT and in nontransplant settings requires further studies. " 04/01/1981 - "Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study." 01/01/1981 - "During initial trials of 5-azacytidine in adults with advanced acute leukemia, we unexpectedly observed acid-base, fluid, and electrolyte abnormalities that contributed directly to the deaths of two early patients. " 04/01/2014 - "Mechanisms of resistance to azacitidine in human leukemia cell lines." 09/01/2013 - "Our data establish hENT1 as a key transporter for the cellular uptake of 5-azacytidine in leukemia cells and raise the possibility that hENT1 expression might be a useful biomarker to predict the efficiency of 5-azacytidine treatments. "
4.	Neoplasms (Cancer) 10/01/2013 - "Long term administration of 5-azacytidine resulted in reduction of DNA methylation of promoter loci, induction of glial differentiation, reduction of cell proliferation and a significant reduction in tumor growth. " 01/01/2015 - "Furthermore, this study identified a novel function of 5-azacytidine in promoting a TET-mediated generation of 5hmC suggesting that the availability of 5-AZA in cancer cells will have various effects on different epigenetic targets. " 11/15/2013 - "Our study also warrants further exploration in the potential therapeutic use of existing epigenetic targeting drugs (e.g., 5-azacytidine, SAHA) to reconstitute CACNA2D3-associated tumor suppression in NPC. " 10/01/2012 - "Numerous drugs that specifically target DNMTs are being tested in ongoing clinical trials for a variety of cancers, and data from finished trials demonstrate that some, such as 5-azacytidine, may even be superior to standard care. " 04/01/2007 - "Considering that 5-azacytidine potentiates hepatocarcinogenesis, more studies are needed to elucidate the efficacy and safety of this drug for cancer control."
5.	Lung Neoplasms (Lung Cancer) 11/01/2010 - "The purpose of this study is to explore the therapeutic potential of regional administration (via the airways) of the demethylating agent 5-azacytidine (5-Aza) for the treatment of early lung cancer. " 10/01/2013 - "Collectively, these findings show that aerosolised 5-azacytidine targets the lung, effectively reprogrammes the epigenome of tumours, and is a promising approach to combine with other drugs for treating lung cancer." 10/01/2013 - "Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model." 11/01/2010 - "5-Azacytidine can reverse the hypermethylation in the human lung cancer cell lines at a nontoxic dose. " 11/01/2010 - "Intratracheally administered 5-azacytidine is effective against orthotopic human lung cancer xenograft models and devoid of important systemic toxicity."

Related Drugs and Biologics

1.	DNA (Deoxyribonucleic Acid)
2.	decitabine (5-aza-2'-deoxycytidine)
3.	Cytarabine (Cytosar-U)
4.	lenalidomide (CC 5013)
5.	gemtuzumab (gemtuzumab ozogamicin)
6.	Histone Deacetylase Inhibitors
7.	A-Form DNA (A-DNA)
8.	Amsacrine (AMSA)
9.	Etoposide (VP 16)
10.	N- (2- aminophenyl)- 4- (N- (pyridin- 3- ylmethoxycarbonyl)aminomethyl)benzamide (MS 275)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Transplants (Transplant)
4.	Homologous Transplantation (Allograft)
5.	Combination Drug Therapy (Combination Chemotherapy)